Cargando…

Influence of indacaterol on daily physical activity in patients with untreated chronic obstructive pulmonary disease

BACKGROUND: Indacaterol, a once-daily, long-acting β(2)-agonist, may improve not only respiratory function, dyspnea symptoms, and quality of life, but also physical activity for patients with chronic obstructive pulmonary disease (COPD). This study aimed to evaluate the effect of 12-week indacaterol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishijima, Yu, Minami, Seigo, Yamamoto, Suguru, Ogata, Yoshitaka, Koba, Taro, Futami, Shinji, Komuta, Kiyoshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4354394/ https://www.ncbi.nlm.nih.gov/pubmed/25767381 http://dx.doi.org/10.2147/COPD.S76836

Ejemplares similares

Amylase-Producing Lung Cancer with a Positive Epidermal Growth Factor Receptor Mutation Treated With Gefitinib: A Case Report
por: Minami, Seigo, et al.
Publicado: (2014)

Ambulatory pulse oximetry monitoring in Japanese COPD outpatients not receiving oxygen therapy
por: Minami, Seigo, et al.
Publicado: (2014)

Outcomes and prognostic factors of chemotherapy for patients with locally advanced or metastatic pulmonary squamous cell carcinoma
por: Minami, Seigo, et al.
Publicado: (2016)

Trajectory of chemotherapy for patients with EGFR wild-type advanced pulmonary adenocarcinoma: a single-institution retrospective study
por: Minami, Seigo, et al.
Publicado: (2017)

Combination chemotherapy of gemcitabine and vinorelbine for pretreated non-small-cell lung cancer: a retrospective study
por: Minami, Seigo, et al.
Publicado: (2015)

Opioid switch from low dose of oral oxycodone to transdermal fentanyl matrix patch for patients with stable thoracic malignancy-related pain
por: Minami, Seigo, et al.
Publicado: (2014)

Neutrophil-to-Lymphocyte Ratio Predicts Overall Survival of Advanced Non-Small Cell Lung Cancer Harboring Mutant Epidermal Growth Factor Receptor
por: Minami, Seigo, et al.
Publicado: (2017)

Pretreatment Glasgow prognostic score and prognostic nutritional index predict overall survival of patients with advanced small cell lung cancer
por: Minami, Seigo, et al.
Publicado: (2017)

Retrospective analysis of outcomes and prognostic factors of chemotherapy for small-cell lung cancer
por: Minami, Seigo, et al.
Publicado: (2016)

Diffuse Alveolar Hemorrhage Induced by Irinotecan for a Patient with Metastatic Thymic Carcinoma: A Case Report and Literature Review
por: Kim, Sung-Ho, et al.
Publicado: (2017)

Indacaterol improves daily physical activity in patients with chronic obstructive pulmonary disease
por: Hataji, Osamu, et al.
Publicado: (2013)

Randomized Phase II trial of paclitaxel and carboplatin followed by gemcitabine switch-maintenance therapy versus gemcitabine and carboplatin followed by gemcitabine continuation-maintenance therapy in previously untreated advanced non-small cell lung cancer
por: Minami, Seigo, et al.
Publicado: (2013)

Lymphocyte to Monocyte Ratio and Modified Glasgow Prognostic Score Predict Prognosis of Lung Adenocarcinoma Without Driver Mutation
por: Minami, Seigo, et al.
Publicado: (2018)

Pretreatment Lymphocyte to Monocyte Ratio as a Prognostic Marker for Advanced Pulmonary Squamous Cell Carcinoma Treated With Chemotherapy
por: Minami, Seigo, et al.
Publicado: (2018)

Gustave Roussy Immune Score Is a Prognostic Factor for Chemotherapy-Naive Pulmonary Adenocarcinoma With Wild-Type Epidermal Growth Factor Receptor
por: Minami, Seigo, et al.
Publicado: (2019)

Comparative efficacy of indacaterol in chronic obstructive pulmonary disease
por: Ribeiro, Marcos, et al.
Publicado: (2012)

Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol
por: Roskell, Neil S, et al.
Publicado: (2014)

Indacaterol for Chronic Obstructive Pulmonary Disease: Systematic Review and Meta-Analysis
por: Chung, Vincent C. H., et al.
Publicado: (2013)

Pulmonary Adenosquamous Cell Carcinoma With Systemic Lymphadenopathy due to Immunoglobulin G4-Related Disease: A Case Report
por: Ikebe, Saori, et al.
Publicado: (2021)

Pretreatment Lung Immune Prognostic Index Is a Prognostic Marker of Chemotherapy and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Minami, Seigo, et al.
Publicado: (2019)

Sarcopenia and Visceral Adiposity Are Not Independent Prognostic Markers for Extensive Disease of Small-Cell Lung Cancer: A Single-Centered Retrospective Cohort Study
por: Minami, Seigo, et al.
Publicado: (2020)

Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Prognostic Markers for Extensive Disease of Small Cell Lung Cancer
por: Minami, Seigo, et al.
Publicado: (2020)

Improving the quality of life in patients with chronic obstructive pulmonary disease: focus on indacaterol
por: Feldman, Gregory J
Publicado: (2013)

Safety and Effectiveness of Indacaterol in Chronic Obstructive Pulmonary Disease Patients in South Korea
por: Yum, Ho-Kee, et al.
Publicado: (2017)

Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study
por: Vincken, Walter, et al.
Publicado: (2014)

A Phase II Study of Tailored-dose S-1 Plus Carboplatin Followed by Maintenance S-1 for Advanced Squamous Cell Lung Cancer: OSAKA-LCSG 1102
por: Yokoi, Takashi, et al.
Publicado: (2019)

Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review
por: Ulrik, Charlotte Suppli
Publicado: (2014)

Gustave Roussy Immune Score and Royal Marsden Hospital Prognostic Score Are Biomarkers of Immune-Checkpoint Inhibitor for Non-Small Cell Lung Cancer
por: Minami, Seigo, et al.
Publicado: (2019)

Sarcopenia and Visceral Adiposity Did Not Affect Efficacy of Immune-Checkpoint Inhibitor Monotherapy for Pretreated Patients With Advanced Non-Small Cell Lung Cancer
por: Minami, Seigo, et al.
Publicado: (2020)

Low Body Mass Index Is an Independent Prognostic Factor in Patients With Non-Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
por: Minami, Seigo, et al.
Publicado: (2019)

High neutrophils and low lymphocytes percentages in bronchoalveolar lavage fluid are prognostic factors of higher in-hospital mortality in diffuse alveolar hemorrhage
por: Kanaoka, Kensuke, et al.
Publicado: (2021)

Growth of Mediastinal Bronchial Artery Aneurysms in a Patient With Bronchiectasis
por: Noda, Yoshimi, et al.
Publicado: (2019)

Direct Switch from Tiotropium to Indacaterol/Glycopyrronium in Chronic Obstructive Pulmonary Disease Patients in Korea
por: Lee, Sang Haak, et al.
Publicado: (2021)

Indacaterol, A Novel Once Daily Inhaled β2-Adrenoreceptor Agonist
por: Roig, Jorge, et al.
Publicado: (2009)

Successful Treatment of Allergic Bronchopulmonary Aspergillosis Using a Combination of Inhaled Fluticasone Furoate/Vilanterol and Oral Voriconazole
por: Nishimatsu, Kanako, et al.
Publicado: (2020)

Indacaterol: a new once daily long-acting beta(2) adrenoceptor agonist
por: Beeh, Kai M, et al.
Publicado: (2010)

Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches
por: Renard, Didier, et al.
Publicado: (2011)

Immediate salbutamol responsiveness does not predict long-term benefits of indacaterol in patients with chronic obstructive pulmonary disease
por: Burgel, Pierre-Régis, et al.
Publicado: (2017)

Combination chemotherapy with intermittent erlotinib and pemetrexed for pretreated patients with advanced non-small cell lung cancer: a phase I dose-finding study
por: Minami, Seigo, et al.
Publicado: (2012)

Lambert-Eaton Myasthenic Syndrome Caused by Nivolumab in a Patient with Squamous Cell Lung Cancer
por: Nakatani, Yuki, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_77n2u1jfqn4mbprp89dkkpn8as